| Oct 17 |
With 50% ownership, OPKO Health, Inc. (NASDAQ:OPK) insiders have a lot riding on the company's future
|
| Oct 11 |
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
|
| Oct 7 |
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
|
| Oct 7 |
NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan
|
| Oct 2 |
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
|
| Sep 26 |
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
|
| Sep 25 |
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
|
| Sep 23 |
OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
|
| Sep 16 |
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
|
| Aug 28 |
Not Enough To Keep OPKO Health Flying
|
